TrianglePUBLICATIONS · 21527590
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Ann Oncol
- Publication date
- 2012 Feb
- First author
- Grignani G
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Grignani G
- type
- Author
- name
- Palmerini E
- type
- Author
- name
- Dileo P
- type
- Author
- name
- Asaftei SD
- type
- Author
- name
- D'Ambrosio L
- type
- Author
- name
- Pignochino Y
- type
- Author
- name
- Mercuri M
- type
- Author
- name
- Picci P
- type
- Author
- name
- Fagioli F
- type
- Author
- name
- Casali PG
- type
- Author
- name
- Ferrari S
- type
- Author
- name
- Aglietta M
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Grignani G
- type
- Author
- name
- Palmerini E
- type
- Author
- name
- Dileo P
- type
- Author
- name
- Asaftei SD
- type
- Author
- name
- D'Ambrosio L
- type
- Author
- name
- Pignochino Y
- type
- Author
- name
- Mercuri M
- type
- Author
- name
- Picci P
- type
- Author
- name
- Fagioli F
- type
- Author
- name
- Casali PG
- type
- Author
- name
- Ferrari S
- type
- Author
- name
- Aglietta M
- type
- Author
- bibliography ids
- nci-bib-407e3830a2bee11e3ad39cfb
- book metadata
- content sha256
- 1d81cd77e07f7fb317d407c86480147180de9d6a990b7037e7a3e2ab3b907802
- document type
- citation
- dois
- 10.1093/annonc/mdr151
- electronic publication date
- display
- 2011 Apr 28
- precision
- day
- year
- 2011
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:21527590
- immutable id
- pubmed:21527590@1d81cd77e07f7fb317d407c86480147180de9d6a990b7037e7a3e2ab3b907802
- journal
- abbreviation
- Ann Oncol
- issn electronic
- 1569-8041
- issn print
- 0923-7534
- issue
- 2
- name
- Annals of oncology : official journal of the European Society for Medical Oncology
- nlm unique id
- 9007735
- pages
- 508-16
- volume
- 23
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 21527590
- provenance
- batch id
- a366a1bc8ed89d8d7ca5
- provider
- NCBI PubMed ESummary
- record sha256
- 23114bba8ee8fa3746e46b744e43e9e08a895d3561270594522ee4169795b2c9
- response sha256
- c4fde29a469958f2f95ac1ef059ab1994169370e37d8293c0823efce81dabbb8
- retrieved at
- 2026-09-09T23:46:40.540025+00:00
- publication date
- display
- 2012 Feb
- precision
- month
- year
- 2012
- publication types
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
Preserved source evidence · Not medical advice